Sex steroids control neuroinflammatory processes in the brain: Relevance for acute ischaemia and degenerative demyelination

Journal of Neuroendocrinology

Volumn 24, Issue 1, 2012, Pages 62-70

  Kipp, M ^a   Berger, K ^a   Clarner, T ^a   Dang, J ^a   Beyer, C ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Astroglia; Chemokine; Cytokine; Demyelination; Ischaemia; Microglia; Oestrogen; Oligodendrocyte; Progesterone

Indexed keywords

ESTROGEN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGESTERONE; RANTES;

BRAIN HYPOXIA; BRAIN ISCHEMIA; DEMYELINATING DISEASE; ENCEPHALITIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN ISCHEMIA; CHEMOKINES; DEMYELINATING DISEASES; ENCEPHALITIS; GONADAL STEROID HORMONES; NEURONS; NEUROTRANSMITTER AGENTS;

EID: 84055191684     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02163.x     Document Type: Review

References (100)

1. Kipp M, Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuroendocrinol 2009; 30: 188-200.
2. Arnold S, Beyer C. Neuroprotection by estrogen in the brain: the mitochondrial compartment as presumed therapeutic target. J Neurochem 2009; 110: 1-11.
3. Yao M, Nguyen TV, Pike CJ. Estrogen regulates Bcl-w and Bim expression: role in protection against beta-amyloid peptide-induced neuronal death. J Neurosci 2007; 27: 1422-1433.
4. Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008; 31: 529-537.
5. Arevalo MA, Santos-Galindo M, Bellini MJ, Azcoitia I, Garcia-Segura LM. Actions of estrogens on glial cells: implications for neuroprotection. Biochim Biophys Acta 2010; 1800: 1106-1112.
6. Garcia-Segura LM, Balthazart J. Steroids and neuroprotection: new advances. Front Neuroendocrinol 2009; 30: v-iv.
7. Dhandapani KM, Brann DW. Role of astrocytes in estrogen-mediated neuroprotection. Exp Gerontol 2007; 42: 70-75.
8. Wagner CK. The many faces of progesterone: a role in adult and developing male brain. Front Neuroendocrinol 2006; 27: 340-359.
9. Dang J, Mitkari B, Kipp M, Beyer C. Gonadal steroids prevent cell damage and stimulate behavioral recovery after transient middle cerebral artery occlusion in male and female rats. Brain Behav Immun 2011; 25: 715-726.
10. Amantea D, Russo R, Bagetta G, Corasaniti MT. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol Res 2005; 52: 119-132.
11. Sherwin BB. Estrogen therapy: is time of initiation critical for neuroprotection? Nat Rev Endocrinol 2009; 5: 620-627.
12. Simpkins JW, Yi KD, Yang SH, Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta 2010; 1800: 11113-11120.
13. Garcia-Segura LM, Arevalo MA, Azcoitia I. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog Brain Res 2010; 181: 251-272.
14. Liu M, Kelley MH, Herson PS, Hurn PD. Neuroprotection by sex steroids. Minerva Endocrinol 2010; 35: 127-143.
15. Sayeed I, Stein DG. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog Brain Res 2009; 175: 219-237.
16. Dziennis S, Jia T, Ronnekleiv O, Hurn PD, Alkayed NJ. Role of signal transducer and activator of transcription-3 in estradiol-mediated neuroprotection. J Neurosci 2007; 27: 7268-7274.
17. Bruce-Keller AJ, Keeling JL, Keller JN, Huang FF, Camondola S, Mattson MP. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 2000; 141: 3646-3656.
18. Ivanova T, Mendez P, Garcia-Segura LM, Beyer C. Rapid stimulation of the PI3-kinase/Akt signalling pathway in developing midbrain neurones by oestrogen. J Neuroendocrinol 2002; 14: 73-79.
19. Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacol 2008; 55: 127-138.
20. Jia J, Guan D, Zhu W, Alkayed NJ, Wang MM, Hua Z, Xu Y. Estrogen inhibits Fas-mediated apoptosis in experimental stroke. Exp Neurol 2009; 215: 48-52.
21. Misiak M, Beyer C, Arnold S. Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons. Biochim Biophys Acta 2010; 1797: 1178-1188.
22. Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008; 149: 3167-3175.
23. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab 2009; 20: 477-482.
24. Gavrilova-Jordan LP, Price TM. Actions of steroids in mitochondria. Semin Reprod Med 2007; 25: 154-164.
25. Kipp M, Karakaya S, Pawlak J, Araujo-Wright G, Arnold S, Beyer C. Estrogen and the development and protection of midbrain dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factor. Front Neuroendocrinol 2006; 27: 376-390.
26. Ivanova T, Karolczak M, Beyer C. Estrogen stimulates GDNF expression in developing hypothalamic neurons. Endocrinology 2002; 143: 3175-3178.
27. Ivanova T, Küppers E, Engele J, Beyer C. Estrogen stimulates brain-derived neurotrophic factor in embryonic mouse midbrain neurons through a membrane-mediated and calcium-dependent mechanism. J Neurosci Res 2001; 66: 221-230.
28. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain-barrier. Trends Pharmacol Sci 2010; 31: 246-254.
29. Ardelt AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, Hurn PD. Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor-alpha in a rodent experimental stroke model. Stroke 2005; 36: 337-341.
30. Pawlak J, Brito V, Küppers E, Beyer C. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res 2005; 138: 1-7.
31. Du S, Sandoval F, Trinh P, Umeda E, Voskuhl R. Estrogen receptor-β ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating disease. Eur J Immunol 2011; 41: 140-150.
32. Gulliver SC. Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol 2010; 120: 105-115.
33. Vegeto E, Benedusi V, Adriana M. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 2008; 29: 507-519.
34. Kipp M, Karakaya S, Johann S, Kampmann E, Mey J, Beyer C. Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in midbrain astrocytes. J Neuroendocrinol 2007; 19: 819-822.
35. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009; 118: 723-733.
36. Hoffmann GE, Merchenthaler I, Zup SL. Neuroprotection by ovarian hormones in animal models of neurological disease. Endocrine 2006; 29: 217-231.
37. Carwile E, Wagner AK, Crago E, Alexander SA. Estrogen and stroke: a review of the current literature. J Neurosci Nurs 2009; 41: 18-25.
38. Wenger NK, Speroff L, Packard B. Cardiovascular heath and disease in women. N Engl J Med 1993; 329: 247-256.
39. Herson PS, Hoerner IP, Hurn PD. Sex, sex steroids and brain injury. Semin Reprod Med 2009; 27: 229-239.
40. Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev 2009; 57: 386-397.
41. Suzuki S, Brown CM, Wise PM. Neuroprotective effects of estrogens following ischemic stroke. Front Neuroendocrinol 2009; 30: 201-211.
42. Singh M, Sumien N, Kyser C, Simpkins JW. Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci 2008; 13: 1083-1089.
43. Rusa R, Alkayed NJ, Crain B, Traystman RJ, Kimes AS, London ED, Klaus JA, Hurn PD. 17β-estradiol reduces stroke injury in estrogen-deficient female animals. Stroke 1999; 30: 1665-1670.
44. Kramer M, Dang J, Baertling F, Denecke B, Clarner T, Kirsch C, Beyer C, Kipp M. TTC staining of damaged brain areas after MCA occlusion in the rat does not constrict quantitative gene and protein analysis. J Neurosci Methods 2010; 187: 84-89.
45. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998; 9: 259-275.
46. Lucas S-M, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Clin Pharmacol 2006; 147: S232-S240.
47. Baggliolini M. Chemokines and leukocyte traffic. Nature 1998; 393: 565-568.
48. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010; 7: 22-30.
49. Szcucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007; 115: 137-146.
50. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/- mice. J Cereb Blood Flow Metab 2010; 30: 769-782.
51. Cross AK, Woodroofe MN. Chemokines induce migration and changes in actin polymerization in adult rat brain microglia and human fetal microglia cell line in vitro. J Neurosci Res 1999; 55: 17-23.
52. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010; 224: 93-100.
53. Denes A, Humphreys N, Lane TE, Grencis R, Rothwell N. Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. J Neurosci 2010; 30: 10086-10095.
54. Terao S, Yilmaz G, Stokes KY, Russell J, Ishikawa M, Kawase T, Granger DN. Blood cell-derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia-reperfusion. Stroke 2008; 39: 2560-2570.
55. Yao Y, Tsirka SE. The C terminus of mouse monocyte chemoattractant protein (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem 2010; 285: 31509-31516.
56. Schilling M, Strecker JK, Schäbitz WR, Ringelstein EB, Kiefer R. Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience 2009; 161: 806-812.
57. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84: 238-249.
58. Babcock AA, Kuziel WA, Rivest S, Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 2003; 23: 7922-7930.
59. Zhang B, Subramanian S, Dziennis S, Jia J, Uchida M, Akiyoshi K, Migliati E, Lewis AD, Vandenbark AA, Offner H, Hurn PD. Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol 2010; 184: 4087-4094.
60. Brown CM, Mulcahey TA, Filipek NC, Wise PM. Production of proinflammatory cytokines and chemokines during neuroinflammation: novel roles for estrogen receptors alpha and beta. Endocrinology 2010; 151: 4916-4925.
61. Chiappetta O, Gliozzi M, Siviglia E, Amantea D, Morrone LA, Berliocchi L, Bagetta G, Corasaniti MT. Evidence to implicate early modulation of interleukin-1beta expression in the neuroprotection afforded by 17beta estradiol in male rats undergone transient middle cerebral artery occlusion. Int Rev Neurobiol 2007; 82: 357-372.
62. King AE, Critchley HO. Oestrogen and progesterone regulation of inflammatory processes in the human endometrium. J Steroid Biochem Mol Biol 2010; 120: 116-126.
63. Jensen F, Woudwyk M, Teles A, Woidacki K, Taran F, Costa S, Malfertheiner SF, Zenclussen AC. Estradiol and progesterone regulate the migration of mast cells from the periphery to the uterus and induce their maturation and degranulation. PLoS ONE 2010; 5: e14409.
64. Gibson CL, Constantin D, Prior MJ, Bath PM, Murphy SP. Progesterone suppresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia. Exp Neurol 2005; 193: 522-530.
65. Ishrat T, Sayeed I, Atif F, Hua F, Stein DG. Progesterone and allopregnanolone attenuate blood-brain-barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol 2010; 226: 183-190.
66. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
67. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol 2006; 18: 145-157.
68. van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000; 26: 2-10.
69. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285-291.
70. Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther 2010; 126: 82-93.
71. Benedetti B, Rovaris M, Rocca MA, Caputo D, Zaffaroni M, Capra R, Bertolotto A, Martinelli V, Comi G, Filippi M. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 2009; 15: 789-794.
72. Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol 2010; 69: 1017-1033.
73. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol 2010; 225: 2-8.
74. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
75. Bebo BF Jr, Fyfe-Johnson A, Adlard K, Beam AG, Vandenbark AA, Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001; 166: 2080-2089.
76. Ito A, Bebo BF Jr, Matejuk A, Zamora A, Silverman M, Fyfe-Johnson A, Offner H. Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol 2001; 167: 542-552.
77. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 1999; 52: 1230-1238.
78. Polanczyk MJ, Jones RE, Subramanian S, Afentoulis M, Rich C, Zakroczymski M, Cooke P, Vandenbark AA, Offner H. T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am J Pathol 2004; 165: 2069-2077.
79. Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci USA 2007; 104: 14813-14818.
80. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 2006; 26: 6823-6833.
81. Lelu K, Delpy L, Robert V, Foulon E, Laffont S, Pelletier L, Engelhardt B, Guery JC. Endogenous estrogens, through estrogen receptor alpha, constrain autoimmune inflammation in female mice by limiting CD4+ T-cell homing into the CNS. Eur J Immunol 2010; 40: 3489-3498.
82. Pettersson A, Ciumas C, Chirsky V, Link H, Huang YM, Xiao BG. Dendritic cells exposed to estrogen in vitro exhibit therapeutic effects in ongoing experimental allergic encephalomyelitis. J Neuroimmunol 2004; 156: 58-65.
83. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7: 841-851.
84. Garay L, Deniselle MC, Meyer M, Costa JJ, Lima A, Roig P, De Nicola AF. Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res 2009; 1283: 177-185.
85. Garay L, Deniselle MC, Lima A, Roig P, De Nicola AF. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol 2007; 107: 228-237.
86. Herrero-Herranz E, Pardo LA, Gold R, Linker RA. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 2008; 30: 162-173.
87. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-276.
88. Onuki M, Ayers MM, Bernard CC, Orian JM. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice. Microsc Res Tech 2001; 52: 731-739.
89. Yates MA, Li Y, Chlebeck P, Proctor T, Vandenbark AA, Offner H. Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis. J Neuroimmunol 2010; 220: 136-139.
90. Yu HJ, Fei J, Chen XS, Cai QY, Liu HL, Liu GD, Yao ZX. Progesterone attenuates neurological behavioral deficits of experimental autoimmune encephalomyelitis through remyelination with nucleus-sublocalized Olig1 protein. Neurosci Lett 2010; 476: 42-45.
91. Pott F, Gingele S, Clarner T, Dang J, Copray S, Baumgartner W, Beyer C, Kipp M. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res 2009; 1305: 137-149.
92. Groebe A, Clarner T, Baumgartner W, Beyer C, Kipp M. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia invasion/proliferation in the mouse cerebellum. Cerebellum 2009; 8: 163-174.
93. Norkute A, Hieble A, Braun A, Johann S, Baumgartner W, Beyer C, Kipp M. Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J Neurosci Res 2009; 87: 1343-1355.
94. Acs P, Kipp M, Komoly S, Beyer C. 17β-estradiol and progesterone treatment prevents demyelinization in an experimental multiple sclerosis animal model. Glia 2009; 57: 807-814.
95. Taylor LC, Puranam K, Gilmore W, Ting JP, Matsushima GK. 17beta-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss. Neurobiol Dis 2010; 39: 127-137.
96. Lorenz L, Dang J, Misiak M, Abolfazl AT, Beyer C, Kipp M. Combined estrogen and progesterone treatment prevents neuronal cell injury in primary cortical but not mesencephalic neurons or neuroblastoma cells. J Neuroendocrinol 2009; 21: 841-849.
97. Kajta M, Trotter A, Lason W, Beyer C. Impact of 17β-estradiol on cytokine-mediated apoptotic effects in primary hippocampal and neocortical cell cultures. Brain Res 2006; 1116: 64-74.
98. Bernstein P, Pohost G. Progesterone, progestins, and the heart. Rev Cardiovasc Med 2010; 11: 228-236.
99. Bulun SE, Cheng YH, Pavone ME, Yin P, Imir G, Utsunomiya H, Thung S, Xue Q, Marsh EE, Tokunaga H, Ishikawa H, Kurita T, Su EJ. 17beta-hydroxysteroid dehydrogesase-2 deficientcy and progesterone resistance in endometriose. Semin Reprod Med 2010; 28: 44-50.
100. Johnson JJ. Carnosol: a promising anti-cancer and anti-inflammatory agent. Cancer Lett 2011; 305: 1-7.